<DOC>
	<DOCNO>NCT02341456</DOCNO>
	<brief_summary>This phase Ib , open-label , multicentre study AZD1775 administer orally monotherapy combination carboplatin paclitaxel Asian patient advance solid tumour .</brief_summary>
	<brief_title>Phase Ib Study AZD1775 Combination With Carboplatin Paclitaxel Adult Asian Patients With Solid Tumours</brief_title>
	<detailed_description>This phase Ib , open label , multicentre study AZD1775 administer orally monotherapy combination carboplatin paclitaxel Asian patient advance solid tumour . The study design allow escalation de-escalation AZD1775 combination carboplatin paclitaxel intensive safety monitoring ensure safety patient . Approximately 12 evaluable patient enrol dose-finding portion study . The total number patient depend upon number combination dose level evaluation necessary define recommend dose clinical evaluation . The propose combination dose : Dose level-1 ; Dose level 1 ; Dose level 2 ( Dose Level 1 tolerate ) . All combination dose Combination Dose level 1 may subject change SRC light emerge data . At least 3 6 evaluable patient require dose find cohort . Once recommend dose clinical evaluation establish , additional 3 6 patient may enrol cohort recommend dose define characterise safety , tolerability , pharmacokinetics , efficacy profile AZD1775 combination paclitaxel carboplatin . If dose subsequently find non-tolerated , alternative dos and/or schedule may explore . This determined SRC .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histological cytological confirmation locally advance metastatic solid tumour , exclude lymphoma , fail respond standard therapy , progress despite standard therapy , standard therapy exist . At least 1 measureable lesion accurately assess baseline computerise tomography ( CT ) magnetic resonance imaging ( MRI ) solid tumour assess use RECIST v1.1 . World Health Organisation performance status 0 1 deterioration previous 2 week minimum life expectancy ≥12 week . Any cytotoxic chemotherapy , investigational agent anticancer drug previous treatment regimen clinical study within 14 day ( investigational agent well characterise PK profile ) 5 × halflives first dose study treatment Patient prescription nonprescription drug product ( ie , grapefruit juice ) know sensitive CYP3A4 substrates CYP3A4 substrate narrow therapeutic index , moderate strong inhibitor inducer CYP3A4 , discontinue 2 week Day 1 dose withheld throughout study 2 week last dose study drug . Coadministration aprepitant study prohibit . AZD1775 inhibitor breast cancer resistance protein ( BCRP ) . The use statins include Atorvastatin substrates BCRP therefore prohibit patient move nonBCRP alternative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>